Company intelligence
Enliven Therapeutics
Discovering and developing next generation precision oncology therapeutics
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.
Verified activity
Signals from Enliven Therapeutics
4 published signals
Research & Knowledge
Enliven Therapeutics partnered with The Max Foundation to share data showing that the average age of diagnosis for CML is 38 in low-and-middle-income countries.
Reported by Enliven Therapeutics
Presence & Recognition
Enliven Therapeutics management team is looking forward to participating in three investor conferences this month including the Wells Fargo 21st Annual Healthcare Conference, the Baird 2026 Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference.
Reported by Enliven Therapeutics
Presence & Recognition
Enliven Therapeutics is participating in the Blood Cancer Awareness Month and World CML Day on September 22.
Reported by Enliven Therapeutics
Presence & Recognition
Enliven Therapeutics will feature an encore presentation of data from its ENABLE Phase 1b clinical trial evaluating ELVN-001 at the Society of Hematologic Oncology Annual Meeting at SOHO 2026.
Reported by Enliven Therapeutics